Last updated: September 3, 2026
Sulfur hexafluoride lipid-type A microspheres are the active ultrasound contrast agent in Bracco’s Lumason in the United States and SonoVue in many international markets. The product is a diagnostic imaging agent, not a therapeutic drug. Its market position is supported by broad echocardiography and radiology use, established hospital procurement channels, and limited substitutability in selected ultrasound examinations. Product-specific revenue is not publicly disclosed, but the commercial trajectory is tied to growth in contrast-enhanced ultrasound, radiology utilization, and the replacement of some CT or MRI examinations.
What is sulfur hexafluoride lipid-type A microspheres?
Sulfur hexafluoride lipid-type A microspheres are gas-filled phospholipid microspheres administered intravenously to enhance ultrasound imaging. The microspheres reflect ultrasound waves and improve visualization of blood flow, cardiac chambers, and focal liver lesions.
| Attribute |
Information |
| Active component |
Sulfur hexafluoride gas in lipid-type A microspheres |
| U.S. brand |
Lumason |
| International brand |
SonoVue |
| U.S. sponsor |
Bracco Diagnostics Inc. |
| Global manufacturer |
Bracco Imaging |
| Dosage form |
Injectable suspension for reconstitution |
| Primary uses |
Echocardiography, liver imaging, selected pediatric cardiac imaging |
| FDA regulatory pathway |
New drug application |
| U.S. NDA |
NDA 203684 |
| First U.S. approval |
October 31, 2014 |
| Therapeutic category |
Ultrasound contrast agent |
The product is used in adults for contrast-enhanced echocardiography and characterization of focal liver lesions. The FDA later expanded the label to include pediatric echocardiography in 2016. The European product SonoVue has been marketed since 2001.[1][2]
What is the market size for Lumason and SonoVue?
The addressable market is the global ultrasound contrast media market, which includes sulfur hexafluoride, perflutren, and human albumin-based products. Public market reports generally estimate the global ultrasound contrast agent market in the low-single-digit billions of dollars, with growth in the mid-single digits depending on the market definition and forecast period. These estimates are not audited and do not isolate Lumason or SonoVue revenue.[3]
The market is concentrated among a small number of products:
| Product |
Active contrast agent |
Main company |
Primary geographic position |
| Lumason / SonoVue |
Sulfur hexafluoride microspheres |
Bracco |
Global |
| Definity |
Perflutren lipid microspheres |
Lantheus |
United States and selected international markets |
| Optison |
Perflutren protein-type A microspheres |
GE HealthCare |
United States and selected markets |
| Sonazoid |
Perfluorobutane microspheres |
GE HealthCare |
Japan and selected international markets |
Bracco’s principal competitive advantage is geographic breadth. SonoVue has been commercially established in Europe and other international markets for more than two decades, while Lumason has a later U.S. launch history.
How does Lumason compare with Definity and Optison?
Lumason competes most directly with Definity in U.S. echocardiography. The products differ in gas composition, shell chemistry, vial configuration, dosing, imaging behavior, and institutional familiarity.
| Factor |
Lumason |
Definity |
Optison |
| Gas |
Sulfur hexafluoride |
Perflutren |
Perflutren |
| Shell |
Phospholipid |
Phospholipid |
Human albumin |
| U.S. sponsor |
Bracco |
Lantheus |
GE HealthCare |
| Core U.S. use |
Echocardiography and liver imaging |
Echocardiography |
Echocardiography |
| Liver indication |
Yes |
No equivalent broad FDA liver indication |
No equivalent broad FDA liver indication |
| Competitive strength |
Broad label and global installed base |
Strong U.S. cardiac presence |
Established cardiac product |
| Main procurement factor |
Clinical utility, price, supply, workflow |
Clinical familiarity and cardiac demand |
Existing hospital contracts |
Lumason’s liver-imaging indication gives Bracco access to a segment that is less directly exposed to cardiac-only competition. Definity has strong brand recognition in U.S. cardiology and benefits from Lantheus’s specialization in diagnostic imaging. Hospital formularies often carry more than one contrast agent because clinical protocols and imaging platforms differ.
What drives demand for sulfur hexafluoride microspheres?
Demand depends on procedure volume rather than chronic prescription use. Key drivers include:
- Growth in echocardiography and cardiac imaging.
- Wider adoption of contrast-enhanced ultrasound.
- Increased use of ultrasound for liver lesion characterization.
- Pediatric cardiac imaging where improved endocardial border definition is required.
- Efforts to reduce radiation exposure and limit reliance on CT.
- Expansion of ultrasound capability in community hospitals and outpatient imaging centers.
- Reimbursement and coding policies for contrast-enhanced ultrasound.
The product has a consumable revenue model. Each imaging procedure can generate repeat demand, but utilization is sensitive to hospital budgets, contrast protocols, reimbursement, and supply continuity.
What is the financial trajectory for Lumason and SonoVue?
Bracco does not report Lumason or SonoVue revenue as a separate public line item. Bracco Imaging reports at the business or portfolio level, which prevents an independently verified product-specific revenue series. The financial trajectory must therefore be inferred from product lifecycle, geographic reach, clinical indications, and market growth.
Early commercialization: Europe and international markets
SonoVue’s European approval in 2001 gave Bracco a long commercialization period before U.S. approval. The product has accumulated clinical evidence, physician familiarity, and regulatory experience across multiple markets. This supports recurring hospital demand and lowers launch risk in new territories.
U.S. expansion: 2014 onward
The U.S. approval of Lumason created a second major revenue base. The later pediatric echocardiography expansion broadened the addressable patient population.[1][2] The U.S. market is commercially important because cardiac ultrasound contrast use is concentrated in high-volume hospitals and carries meaningful procedural value.
Mature-growth phase
Lumason and SonoVue are mature products, but the category remains capable of growth. The main financial opportunity is increased penetration of contrast-enhanced ultrasound rather than large price increases. Margin performance depends on manufacturing scale, vial utilization, distributor discounts, hospital contracting, and the cost of maintaining sterile injectable production.
The principal limitation is the absence of publicly disclosed product sales. Any estimate assigning a precise annual revenue figure to Lumason or SonoVue without Bracco disclosure should be treated as a market-model estimate rather than reported financial data.
What patents protect Lumason and SonoVue?
The core composition is a gas-filled lipid microsphere. Early patent families covering ultrasound contrast microspheres, phospholipid shells, preparation methods, and gas stabilization were generally filed in the 1980s and 1990s. The earliest foundational patents would ordinarily have expired by now under standard patent-term rules.
The commercial protection today is more likely to depend on:
- Later formulation and manufacturing patents.
- Device or vial-reconstitution configurations.
- Process control for sterile microsphere production.
- Trade secrets covering particle-size distribution and manufacturing yield.
- Regulatory exclusivity and clinical-label differentiation.
- Trademarks and hospital contracting.
- Manufacturing scale and quality-system barriers.
A definitive live-patent determination requires a jurisdiction-specific review of national patent registers, continuations, terminal disclaimers, and patent-term adjustments. Public U.S. FDA materials do not identify a current patent-based exclusivity period for Lumason comparable to a small-molecule Orange Book exclusivity strategy.
What is the Orange Book status of Lumason?
Lumason is approved under NDA 203684. FDA’s Orange Book framework is primarily used for approved drug products and patent certifications associated with abbreviated new drug applications. Contrast agents can be approved drugs without having a commercially significant Orange Book patent estate.
No broad, publicly visible Orange Book patent barrier is generally associated with Lumason comparable to the listed patent portfolios of major branded small-molecule products. The principal regulatory questions for a competing product would involve:
- Whether an ANDA pathway is available.
- Whether the proposed product can demonstrate pharmaceutical equivalence.
- Whether the microsphere structure and performance are sufficiently comparable.
- Whether clinical or imaging-performance data are required.
- Whether the FDA treats the product as an injectable drug requiring a more complex development program.
When does Lumason lose exclusivity?
The relevant exclusivity periods are not equivalent to a single patent expiration date.
| Protection type |
Position |
| FDA approval |
October 31, 2014 |
| Pediatric exclusivity |
Six-month extension was associated with qualifying pediatric labeling work |
| New chemical entity exclusivity |
Not the principal commercial protection typically cited for Lumason |
| Core early composition patents |
Generally expected to be expired |
| Current commercial protection |
Manufacturing know-how, regulatory know-how, trademarks, clinical adoption, and possible later patent families |
| Biosimilar exclusivity |
Not applicable because Lumason is a drug, not a biologic |
Lumason does not have biosimilar risk. The relevant threat is generic or follow-on ultrasound contrast competition.
What generic entry risks exist for sulfur hexafluoride microspheres?
Generic entry risk is moderate but technically complex. A competitor must reproduce a sterile injectable suspension with consistent microsphere concentration, gas retention, particle-size distribution, reconstitution behavior, stability, and imaging performance.
Regulatory barriers
A potential competitor may face difficulty establishing equivalence through conventional pharmaceutical measurements alone. FDA approval could require comparative characterization, pharmacokinetic or safety information, and clinical imaging data depending on the proposed pathway and product differences.
The product is not a conventional tablet with a readily measurable active-ingredient concentration. The functional attributes of the microspheres are central to performance. This can increase development cost and delay launch even when basic composition patents have expired.
Manufacturing barriers
Manufacturing is a significant barrier. Relevant controls include:
- Gas incorporation into the microsphere population.
- Lipid-shell consistency.
- Sterility and particulate control.
- Vial filling and headspace management.
- Reconstitution time and handling.
- Batch-to-batch acoustic performance.
- Stability during distribution.
A generic competitor would also need reliable access to specialized sterile manufacturing capacity. These barriers favor established contrast-agent manufacturers and reduce the likelihood of rapid, broad generic substitution.
Which companies are challenging Bracco in ultrasound contrast?
Lantheus is Bracco’s most important U.S. competitor through Definity. GE HealthCare competes through Optison and maintains a broader diagnostic imaging relationship with hospitals. Regional products, including Sonazoid in Japan, compete in specific liver-imaging and contrast-enhanced ultrasound markets.
The competitive landscape is shaped less by traditional pharmacy substitution and more by:
- Hospital formulary decisions.
- Imaging department protocols.
- Radiologist and cardiologist familiarity.
- Ultrasound equipment compatibility.
- Supply reliability.
- Contract pricing.
- Regulatory label breadth.
Bracco also benefits from having a global diagnostic imaging portfolio, while Lantheus has a concentrated position in precision diagnostics and imaging agents. The commercial balance depends on procedure mix: cardiac-heavy institutions may favor Definity, while centers using contrast-enhanced liver ultrasound may place greater value on Lumason.
What patent litigation or Paragraph IV challenges affect Lumason?
No major publicly established Paragraph IV litigation campaign against Lumason is a central feature of the product’s current commercial profile. The absence of prominent litigation does not eliminate generic risk. It indicates that the immediate competitive issue is more likely to be product development and regulatory approval than a high-profile patent contest.
For a future ANDA filer, the risk assessment would focus on:
- Any listed patents in the FDA Orange Book at the time of filing.
- Patent families covering later formulations or manufacturing methods.
- Whether the proposed product uses the same or different microsphere architecture.
- The possibility of a 30-month stay following a Paragraph IV notice.
- Injunctive relief based on process or formulation claims.
- Regulatory exclusivity and clinical-label restrictions.
What licensing deals affect Lumason?
Bracco’s commercial model is primarily based on internal development, manufacturing, and regional commercialization of its imaging portfolio. No widely reported transaction has changed ownership of the core Lumason or SonoVue franchise. Regional distribution and commercialization arrangements may exist, but they do not appear to create the same strategic exposure as a major asset sale or co-development transaction.
The commercial value of the product is tied to Bracco’s control over manufacturing and global regulatory registrations. Any licensing transaction would likely focus on regional distribution, local registration, or manufacturing support rather than transfer of the global franchise.
What is the FDA regulatory status of Lumason?
Lumason is FDA-approved for specified adult and pediatric ultrasound imaging uses. The label includes important warnings concerning serious cardiopulmonary reactions, hypersensitivity, and administration-related risks. The product must be administered by personnel prepared to manage acute reactions, consistent with the FDA-approved labeling.[1]
The product’s regulatory status is stable, but continued commercial performance depends on maintaining compliance with sterile manufacturing requirements, pharmacovigilance obligations, and labeling controls.
How strong is the patent estate for sulfur hexafluoride microspheres?
The patent estate is stronger as a manufacturing and know-how platform than as a basic composition monopoly.
| Protection dimension |
Relative strength |
| Foundational composition claims |
Low to moderate because early patents are aged |
| Product-specific formulation claims |
Moderate if later patents remain enforceable |
| Manufacturing process |
Moderate to high |
| Sterile injectable production |
High practical barrier |
| Regulatory and clinical data |
Moderate |
| Trademark and brand recognition |
Moderate |
| Hospital contracting and supply reliability |
Moderate to high |
| Biosimilar protection |
Not applicable |
The most durable barriers are operational. A follow-on company may be able to avoid expired composition claims but still face difficulty matching commercial-scale product quality.
What are the likely generic launch scenarios?
Scenario 1: No near-term generic launch
This is the most commercially stable scenario if development economics remain unattractive. The market is specialized, hospital-driven, and technically demanding. Bracco retains pricing and volume protection through manufacturing reliability and clinical adoption.
Scenario 2: One specialized follow-on entrant
A technically capable injectable manufacturer could enter with a product focused on cardiac imaging. Initial penetration would likely be limited to price-sensitive institutions and tenders.
Scenario 3: Multiple contrast-agent entrants
This scenario would require a clear regulatory pathway, accessible manufacturing capacity, and sufficient market growth to support several entrants. Competition would place pressure on hospital contract pricing and could reduce Bracco’s share in high-volume accounts.
Scenario 4: Label-driven segmentation
A competitor could enter with a narrower cardiac indication while Bracco retains an advantage in liver imaging and pediatric applications. This would produce partial rather than full substitution.
What is the revenue exposure for Bracco?
Product-specific revenue exposure cannot be calculated from public filings because Bracco does not separately disclose Lumason or SonoVue sales. The strategic exposure is still material because the products occupy a recurring-use segment across multiple geographies.
Revenue sensitivity is highest to:
- Contrast-enhanced ultrasound adoption.
- U.S. cardiac procedure volume.
- European and Asian hospital tenders.
- Manufacturing disruptions.
- Price competition from Definity and future follow-on products.
- Reimbursement for contrast-enhanced liver imaging.
- Expansion of ultrasound use outside tertiary hospitals.
The franchise has a favorable lifecycle profile: no chronic adherence risk, repeat procedural use, broad international presence, and clinical utility across cardiac and radiology workflows. Its main financial constraints are limited category size, hospital purchasing pressure, and the absence of a strong patent-based premium after the foundational patent period.
Key Takeaways
- Sulfur hexafluoride lipid-type A microspheres are marketed as Lumason in the U.S. and SonoVue internationally.
- Bracco controls the principal global franchise.
- The FDA approved Lumason in 2014 under NDA 203684; pediatric cardiac use was added later.
- Product-specific revenue is not publicly disclosed, so precise Lumason or SonoVue sales estimates are not reported financial data.
- The market is driven by ultrasound procedure volume and adoption of contrast-enhanced imaging.
- Definity is the strongest U.S. competitor, with Optison as a secondary competitor.
- Biosimilar risk does not apply. Generic and follow-on contrast-agent risk does.
- Foundational composition patents are generally aged; manufacturing, sterility, formulation, and process know-how are more durable barriers.
- No major publicly established Paragraph IV litigation campaign currently defines the franchise.
- The most likely competitive threat is gradual hospital-level price and formulary pressure rather than an immediate broad generic conversion.
FAQs About Sulfur Hexafluoride Lipid-Type A Microspheres
Is Lumason the same product as SonoVue?
Yes. Lumason and SonoVue are regional brand names for Bracco’s sulfur hexafluoride lipid-type A microsphere ultrasound contrast agent, subject to local labeling and regulatory differences.
Is sulfur hexafluoride microsphere contrast safe for children?
Lumason has FDA-approved pediatric echocardiography use. Administration must follow the approved label, including warnings, contraindications, and monitoring requirements.[1]
Can sulfur hexafluoride microspheres be substituted with Definity?
Not automatically. Both are ultrasound contrast agents, but they use different gases and product architectures. Substitution depends on the imaging indication, institutional protocol, product availability, and physician judgment.
Does Lumason have a biosimilar competitor?
No. Lumason is regulated as a drug contrast agent rather than a biologic subject to the biosimilar pathway. A competitor would pursue a generic or follow-on drug strategy.
Why is generic manufacturing difficult for ultrasound contrast agents?
Performance depends on microsphere size, shell composition, gas retention, sterility, reconstitution, stability, and acoustic behavior. These attributes create manufacturing and comparability challenges beyond ordinary active-ingredient replication.
References
- U.S. Food and Drug Administration. (2023). Lumason prescribing information. Bracco Diagnostics Inc. https://www.accessdata.fda.gov
- U.S. Food and Drug Administration. (2014). Approval letter for NDA 203684: Lumason. https://www.accessdata.fda.gov
- Grand View Research. (2024). Contrast media market size, share and trends analysis report. https://www.grandviewresearch.com
- Bracco Imaging. (2024). Diagnostic imaging products and corporate information. https://www.braccoimaging.com
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files
